Monoclonal Antibody IV Therapy

We no longer can provide Monoclonal Antibody Infusion due to the FDA withdrawal of the approval.

In nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease, Remdesivir should be started within 7 days of symptom onset and administered for 3 days.

For more information, please contact our IV Therapy Department at 843.758.0044